PDF(1265 KB)
Cost-utility analysis of trametinib plus dabrafenib versus vemurafenib in the treatment of metastatic melanoma with BRAF V600 mutation
ZHOU Xiao-ying, SUN Guo-jun
Chinese Journal of Hospital Pharmacy ›› 2022, Vol. 42 ›› Issue (17) : 1830-1833.
PDF(1265 KB)
PDF(1265 KB)
Cost-utility analysis of trametinib plus dabrafenib versus vemurafenib in the treatment of metastatic melanoma with BRAF V600 mutation
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
